0001140361-24-024333.txt : 20240503
0001140361-24-024333.hdr.sgml : 20240503
20240503160609
ACCESSION NUMBER: 0001140361-24-024333
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240501
FILED AS OF DATE: 20240503
DATE AS OF CHANGE: 20240503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wotton Paul K
CENTRAL INDEX KEY: 0001300997
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35280
FILM NUMBER: 24913038
MAIL ADDRESS:
STREET 1: C/O ANTARES PHARMA, INC.
STREET 2: 707 EAGLEVIEW BOULEVARD, SUITE 414
CITY: EXTON
STATE: PA
ZIP: 19341
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vericel Corp
CENTRAL INDEX KEY: 0000887359
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 943096597
STATE OF INCORPORATION: MI
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7349305555
MAIL ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC
DATE OF NAME CHANGE: 19960428
4
1
form4.xml
FORM 4
X0508
4
2024-05-01
0000887359
Vericel Corp
VCEL
0001300997
Wotton Paul K
C/O VERICEL CORPORATION
64 SIDNEY STREET
CAMBRIDGE
MA
02139
true
false
Common Stock
2024-05-01
4
M
0
3200
A
30002
D
Restricted Stock Unit
2024-05-01
4
M
0
3200
A
Common Stock
3200
0
D
Stock Option (Right to Buy)
47.08
2024-05-01
4
A
0
8000
0
A
2034-05-01
Common Stock
8000
8000
D
Restricted Stock Unit
2024-05-01
4
A
0
3200
0
A
Common Stock
3200
3200
D
The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.
Upon the vesting of RSUs granted to the Reporting Person on May 3, 2023, the Reporting Person deferred the receipt of 3,200 shares of Common Stock and instead received 3,200 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
These RSUs vest 100% on the earlier of May 3, 2024, or the date of the first Annual Meeting of Stockholders following May 3, 2023.
No expiration date for this type of award.
The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.
These RSUs vest 100% on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024.
/s/ Sean Flynn, as Attorney-in-Fact for Paul Wotton
2024-05-03